Capricor Stock Rallies as FDA Opens Path for Revised Deramiocel Filing in Duchenne Muscular Dystrophy

Key Points

• Capricor Therapeutics, Inc. plans to amend its biologics license application, or BLA, for deramiocel after an FDA advisory committee voted 9–3 against the therapy’s effectiveness for Duchenne muscular dystrophy-related cardiomyopathy.
• The FDA indicated it is willing to review an amendment that would support a more focused proposed indication tied to the HOPE-3 trial’s primary endpoint: upper-limb function.
• Capricor expects to include 24-month results from the HOPE-3 open-label extension and additional analyses of its existing dataset.
• The amendment is expected to delay the current August 22 FDA decision date, and deramiocel remains unapproved.

Revised Filing Shifts Focus From Heart Function to Upper-Limb Outcomes

Capricor Therapeutics (Nasdaq: CAPR) is seeking to reshape its regulatory case for deramiocel, an investigational allogeneic cell therapy for Duchenne muscular dystrophy, or DMD. The company’s existing BLA seeks approval for DMD-associated cardiomyopathy, a serious weakening of the heart muscle associated with the disease.

Following the advisory committee’s negative vote on the cardiomyopathy evidence, Capricor said it plans to submit an amendment supporting a refined indication based on upper-limb function. The Phase 3 HOPE-3 study measured upper-limb function as its primary endpoint, while cardiac function was assessed as a secondary endpoint.

FDA Willingness to Review Offers CAPR a New Regulatory Path

The FDA has indicated it will review Capricor’s planned amendment. Capricor expects the package to include 24-month results from the HOPE-3 open-label extension, along with further analyses of clinical data already submitted to the agency.

This is an important regulatory development because it provides CAPR with a possible route to preserve its current review process following the advisory committee setback. It does not, however, represent FDA approval, an FDA agreement that the data demonstrate effectiveness, or a commitment that the revised indication will be accepted.

Advisory Committee Still Raised Questions About the Evidence

At the July 29 FDA advisory committee meeting, the panel voted 9–3 against deramiocel’s effectiveness for cardiomyopathy associated with DMD. Committee members questioned the strength of the evidence for cardiac benefit and debated the statistical analysis of the HOPE-3 trial.

Some panelists expressed greater openness to a potential upper-limb benefit than to the cardiac finding, though they still described the upper-limb evidence as limited or fragile. The debate matters because Capricor’s revised approach will need to persuade the FDA that the upper-limb endpoint and longer-term supporting data provide sufficient evidence for the newly proposed indication.

Market Reaction Reflects Renewed Approval Hopes

CAPR shares rose 71% to $7.19 at the Friday market open, compared with a prior closing price of $4.21. Even after the move, the shares remained well below the roughly $20 level they traded at before the advisory committee vote.

The stock reaction reflects investor interest in the possibility of a revised filing and an extended FDA review. It does not remove the regulatory uncertainty created by the negative advisory committee vote, which is nonbinding but often influential in FDA decision-making.

Investors Await Filing Details and New FDA Timing

Capricor has not finalized the timing of its amendment. Once received, the FDA is expected to extend the August 22 Prescription Drug User Fee Act, or PDUFA, action date to allow time to review the new material.

Investors may watch for:

• The exact language of the proposed upper-limb-function indication
• Submission of the BLA amendment and the FDA’s revised action date
• The 24-month HOPE-3 open-label extension results
• FDA feedback on the strength of the primary-endpoint evidence
• Manufacturing, labeling, and commercial-readiness updates
• Financing needs if the review timeline extends further

Deramiocel has received FDA designations including Orphan Drug, Regenerative Medicine Advanced Therapy, and Rare Pediatric Disease designations, but it has not been approved for commercial use in any indication.